Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
STALICLA Starts Phase 3 DDI Study of STP7 to Treat Cocaine Use Disorder in the U.S.
Details : STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) that was approved in 2022 in the United States and the European Union, and it is the only FDA-approved insomnia medication being evaluated in this study.
Product Name : Quviviq
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Daridorexant HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5...
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Product Name : STP7
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : HMNC Brain Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resist...
Product Name : Ketabon
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : HMNC Brain Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazindol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quilience (Mazindol ER), the Company's lead product candidate and proprietary extended-release formulation of Mazindol (Mazindol ER), is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypers...
Product Name : Quilience
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Mazindol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACT-539313
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2a Study Results in Binge Eating Disorder
Details : ACT-539313, a selective orexin-1 receptor antagonist, did not show an improvement over placebo in reducing the number of binge eating days per week in adult patients with moderate to severe binge eating disorder – the primary endpoint was therefore not...
Product Name : ACT-539313
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : ACT-539313
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mazindol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, used for to treat narcolepsy in comp...
Product Name : Quilience
Product Type : Controlled Substance
Upfront Cash : Undisclosed
December 03, 2021
Lead Product(s) : Mazindol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement